MedDataX Logo

Rehabilitation Required Due to Clinical Disorders After Severe Covid-19 Infection

NCT ID: NCT04681755

Last Updated: 2020-12-28

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

55 participants

Study Classification

OBSERVATIONAL

Study Start Date

2020-05-19

Study Completion Date

2021-05-19

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Due to the emergence of an epidemic cluster in Mulhouse, a city located 100 km south of Strasbourg, Alsace was one of the first French regions to be affected by the coronavirus (SARS-CoV-2 or COVID-19). As a result, all hospitals in the region, including both Strasbourg University Hospitals, had to deal with the epidemic wave earlier and more intensely than the rest of France. At the time of writing this article, 6 weeks after the start of the epidemic, we have counted 998 hospital deaths in our region, i.e., an intrahospital mortality rate linked to COVID-19 of 5.3 deaths per 10,000 inhabitants (https://dashboard.covid19.data.gouv.fr/).

Currently, our intensive care unit still has a large number of patients hospitalized for COVID-19. Some of these patients have severe damage to one or more organs, and in particular a neurological or respiratory deficit suggesting that they will need post-resuscitation rehabilitation. The primary aim is to assess the neurological disorder after severe SARS-CoV-2 infection and the second is the respiratory impairment evaluation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Covid19

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Rehabilitation SARS-CoV-2 COVID-19 Neurological function Respiratory disorder Intensive care unit

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Adult patient (≥18 years old)
* Patient hospitalized in surgical intensive care at the New Civil Hospital between February 24 and April 15, 2020.
* Patient with a SARS-CoV-2 infection documented by RT-PCR or with lesions suggestive on chest CT.
* Patient who has given his consent for the use of his data for the purposes of this research

Exclusion Criteria

* Patient without documentation of SARS-CoV-2 infection (RT-PCR or chest scanner)
* Patient who expressed his opposition to participating in the study
* Subject under safeguard of justice
* Subject under guardianship or guardianship
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital, Strasbourg, France

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Strasbourg University Hospitals - Anesthesia and surgical resuscitation service

Strasbourg, , France

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

France

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Walid Oulehri, MD

Role: CONTACT

Phone: 33 3 69 55 12 71

Email: [email protected]

Saïd CHAYER, PhD, HDR

Role: CONTACT

Phone: 33 3 88 11 66 90

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Walid Oulehri, MD

Role: primary

Saïd CHAYER, PhD, HDR

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

7725

Identifier Type: -

Identifier Source: org_study_id